Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Fraser syndrome and mouse blebbed phenotype caused by mutations in FRAS1/Fras1 encoding a putative extracellular matrix protein.

Authors: McGregor, L  Makela, V  Darling, SM  Vrontou, S  Chalepakis, G  Roberts, C  Smart, N  Rutland, P  Prescott, N  Hopkins, J  Bentley, E  Shaw, A  Roberts, E  Mueller, R  Jadeja, S  Philip, N  Nelson, J  Francannet, C  Perez-Aytes, A  Megarbane, A  Kerr, B  Wainwright, B  Woolf, AS  Winter, RM  Scambler, PJ 
Citation: McGregor L, etal., Nat Genet. 2003 Jun;34(2):203-8.
Pubmed: (View Article at PubMed) PMID:12766769
DOI: Full-text: DOI:10.1038/ng1142

Fraser syndrome (OMIM 219000) is a multisystem malformation usually comprising cryptophthalmos, syndactyly and renal defects. Here we report autozygosity mapping and show that the locus FS1 at chromosome 4q21 is associated with Fraser syndrome, although the condition is genetically heterogeneous. Mutation analysis identified five frameshift mutations in FRAS1, which encodes one member of a family of novel proteins related to an extracellular matrix (ECM) blastocoelar protein found in sea urchin. The FRAS1 protein contains a series of N-terminal cysteine-rich repeat motifs previously implicated in BMP metabolism, suggesting that it has a role in both structure and signal propagation in the ECM. It has been speculated that Fraser syndrome is a human equivalent of the blebbed phenotype in the mouse, which has been associated with mutations in at least five loci including bl. As mapping data were consistent with homology of FRAS1 and bl, we screened DNA from bl/bl mice and identified a premature termination of mouse Fras1. Thus, the bl mouse is a model for Fraser syndrome in humans, a disorder caused by disrupted epithelial integrity in utero.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 1598960
Created: 2007-01-08
Species: All species
Last Modified: 2007-01-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.